PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience

PURPOSE: Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven efficacy in treatment of BReast CAncer (BRCA) gene mutation-positive platinum-sensitive ovarian cancers. There is paucity of data for their role in platinum-resistant ovarian cancer (PROC). We report here retrospective analysis of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Glob Oncol
Main Authors: Agarwal, Amit, Baghmar, Saphalta, Dodagoudar, Chandragouda, Qureshi, Suhail, Khurana, Aseem, Vaibhav, Vikas, Kumar, Guresh
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8162970/
https://ncbi.nlm.nih.gov/pubmed/33852339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/GO.20.00269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados